700 patients110,866 observations180 daysLIVE

Patient P-02395

Synthetic patientMETA-24 · Day 170 · 35–44 · M · baseline S12Open companion preview
Therapy response
Improving
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
35%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S12
  2. Day 16 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 22 DT-01 recommendedDosing / Timing Recommendation DT-01
  4. Day 23 Patient acceptedStarted DT-01 in the companion
  5. Day 28 GI symptom burden −15% vs expectedDosing / Timing Recommendation DT-01
  6. Day 34 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 16.

Primary contributors, last 14 days
  • Inflammatory activity+12
  • GI instability+11
  • Nutritional resilience-8
  • Treatment adherence+5

What helped?

  • Dosing / Timing Recommendation DT-01Day 22
    Result: symptom burden −15%
LIFE OS recommendation
Dietary Support Protocol NP-02
41%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 50% showed improvement
  • median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 43/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 43/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
66 ms
Sleep
7.2 h
Steps
3,957
Resting HR
66 bpm
Daily log: GI score 37, nutritional resilience 50, adherence 97.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • No additional supplements this week
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0220348%S0961
P-0222346%S20HY-01improved49
P-0246144%S0456
P-0205243%S11HY-01no change48
P-0239442%S1262
P-0246742%S0255
P-0247042%S1160
P-0257342%S1052
P-0261642%S0651
P-0235141%S1651
P-0253841%S02GI-04improved59
P-0258841%S0546